Autolus Therapeutics Ltd (AUTL NASDAQ) stock market data APIs
$1.5267
-0.02(-1.3%)
as of December 10, 2025
Try our APIs with
free plan!
Autolus Therapeutics Ltd Financial Data Overview
Price chart is built with
Anychart
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Prev. Close
1.5267
Open
1.5059
High
1.5591
Low
1.4691
52 wk Range
1.105-2.8
Market Cap
407 M
Shares Outstanding
266 M
Revenue
51 128 K
EPS
-0.3
Beta
2.008
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Autolus Therapeutics Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Autolus Therapeutics Ltd data using free add-ons & libraries
Get Autolus Therapeutics Ltd Fundamental Data
Autolus Therapeutics Ltd Fundamental data includes:
- Net Revenue: 51 128 K
- EBITDA: -264 679 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.2244
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Autolus Therapeutics Ltd News
New
3 Promising Penny Stocks With Market Caps Over $70M
With the recent surge in U.S. stock markets following the Federal Reserve's interest rate cuts, investors are keenly observing how these changes might impact various sectors. While major indices like ...
Autolus Reveals Latest Phase I Findings For Obe-cel In Hard-to-Treat Lupus
(RTTNews) - Autolus Therapeutics (AUTL) presented updated clinical data from its CARLYSLE trial in patients with severe refractory systemic lupus erythematosus at the American Society of Hematology (A...
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-ce...
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
